TY - JOUR
T1 - ASSOCIATIONS BETWEEN DYSGLYCEMIA, RETINAL NEURODEGENERATION, AND MICROALBUMINURIA IN PREDIABETES AND TYPE 2 DIABETES
AU - Kirthi, Varo
AU - Zuckerman, Benjamin P
AU - Alam, Uazman
AU - Bunce, Catey
AU - Hopkins, David
AU - Jackson, Timothy L
PY - 2022/3/1
Y1 - 2022/3/1
N2 - Purpose: To explore the association between retinal neurodegeneration and metabolic parameters in progressive dysglycemia. Method: A cross-sectional study was performed on 68 participants: normal glucose tolerance (n = 23), prediabetes (n = 25), and Type 2 diabetes without diabetic retinopathy (n = 20). Anthropometric assessment and laboratory sampling for HbA1c, fasting glucose, insulin, c-peptide, lipid profile, renal function, and albumin-to-creatinine ratio were conducted. Central and pericentral macular thicknesses on spectral domain optical coherence tomography were compared with systemic parameters. Results: Baseline demographic characteristics were similar across all groups. Cuzick's trend test revealed progressive full-thickness macular thinning with increasing dysglycemia across all three groups (P = 0.015). The urinary albumin-to-creatinine ratio was significantly correlated with full-thickness superior (R = 20.435; P = 0.0002), inferior (R = 20.409; P = 0.0005), temporal (R = 20.429; P = 0.003), and nasal (R = 20.493; P, 0.0001) pericentral macular thinning, after post hoc Bonferroni adjustment. There was no association between macular thinning and waist circumference, body mass index, blood pressure, lipid profile, or insulin resistance. Conclusion: Progressive dysglycemia is associated with macular thinning before the onset of visible retinopathy and occurs alongside microalbuminuria. Retinal neurodegenerative changes may help identify those most at risk from dysglycemic end-organ damage.
AB - Purpose: To explore the association between retinal neurodegeneration and metabolic parameters in progressive dysglycemia. Method: A cross-sectional study was performed on 68 participants: normal glucose tolerance (n = 23), prediabetes (n = 25), and Type 2 diabetes without diabetic retinopathy (n = 20). Anthropometric assessment and laboratory sampling for HbA1c, fasting glucose, insulin, c-peptide, lipid profile, renal function, and albumin-to-creatinine ratio were conducted. Central and pericentral macular thicknesses on spectral domain optical coherence tomography were compared with systemic parameters. Results: Baseline demographic characteristics were similar across all groups. Cuzick's trend test revealed progressive full-thickness macular thinning with increasing dysglycemia across all three groups (P = 0.015). The urinary albumin-to-creatinine ratio was significantly correlated with full-thickness superior (R = 20.435; P = 0.0002), inferior (R = 20.409; P = 0.0005), temporal (R = 20.429; P = 0.003), and nasal (R = 20.493; P, 0.0001) pericentral macular thinning, after post hoc Bonferroni adjustment. There was no association between macular thinning and waist circumference, body mass index, blood pressure, lipid profile, or insulin resistance. Conclusion: Progressive dysglycemia is associated with macular thinning before the onset of visible retinopathy and occurs alongside microalbuminuria. Retinal neurodegenerative changes may help identify those most at risk from dysglycemic end-organ damage.
UR - http://www.scopus.com/inward/record.url?scp=85125005779&partnerID=8YFLogxK
U2 - 10.1097/IAE.0000000000003337
DO - 10.1097/IAE.0000000000003337
M3 - Article
C2 - 35188489
SN - 0275-004X
VL - 42
SP - 442
EP - 449
JO - Retina
JF - Retina
IS - 3
ER -
